Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer

Ya-Nan Li, Yang Wu, Feng-Wen Deng, Ying Lu, Guo-Bin Song, Lin Xiang, Tian Peng, Xue-Xin Cheng, Hou-Qun Ying

Therapeutic Advances in Medical Oncology

Published online on January 07, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Cancer-derived inflammation has been shown to attenuate the efficacy of chemotherapy (CT) in colorectal cancer. However, its role in clinical response to bevacizumab (Bev) remains unclear in patients with metastatic colorectal cancer (mCRC)....